Previous 10 |
GAITHERSBURG, Md., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 1, 2018 at 5:00 pm (Eastern Time) to discuss the financial results for the third quarter of 2018, recent business developments, revenue guidance for ...
Currently trading at 0.52x its book value per share after several equity transactions, Altimmune (ALT) seems a bit undervalued as compared to peers. The company sold large amount of warrants that investors should not appreciate. With that, other peers are trading at 1.95x-4.4x book value per s...
Emergent BioSolutions (NYSE: EBS ) has completed its acquisition of PaxVax, a company focused on developing, manufacturing, and commercializing specialty vaccines that protect against existing and emerging infectious diseases. More news on: Emergent BioSolutions Inc., Healthcare stocks n...
GAITHERSBURG, Md., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed its acquisition of PaxVax, a company focused on developing, manufacturing, and commercializing specialty vaccines that protect against existing and emerging infe...
The following slide deck was published by Emergent BioSolutions Inc. in conjunction with this Read more ...
Emergent Biosolutions ( EBS ) is a global life sciences company focused on providing to civilian and military populations specialty products and services that address accidental, intentional and naturally emerging public health threats, explain Tom Bishop , small cap expert and editor of...
NEW YORK, Sept. 05, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Emergent Biosolutions Inc. (NYSE:EBS), LGI Homes, Inc. (NASDAQ:LGIH), Su...
Emergent BioSolutions Inc. (EBS) Acquisition of Adapt Pharma and its Flagship Product NARCAN Nasal Spray Conference Call August 28, 2018 05:00 PM ET Executives Bob Burrows - Vice President, Investor Relations Dan Abdun-Nabi - Chief Executive Officer Bob Kramer - President, Chief ...
Acquisition advances Emergent’s mission, vision and strategic growth plan by: Diversifying and expanding company’s presence within the public health threats market to respond to the opioid crisis, declared a public health emergency by the U.S. government Broadening the ...
News, Short Squeeze, Breakout and More Instantly...
Emergent Biosolutions Inc. Company Name:
EBS Stock Symbol:
NYSE Market:
Emergent Biosolutions Inc. Website:
New video and radio segments raise awareness of a potentially life-saving, three-step method that anyone can use to respond in a suspected opioid poisoning GAITHERSBURG, Md., July 24, 2024 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSE: EBS) announced the launch of a new opio...
GAITHERSBURG, Md., July 23, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, August 6, 2024, at 5:00 pm eastern time to discuss the financial results for the second quarter 2024, key business updates, revenue guidance for the third quarter of...
The extension to a four-year shelf-life helps improve naloxone access as communities continue to grapple with the growing opioid epidemic; product with the extended shelf life has officially begun shipping WINNIPEG, Manitoba, July 22, 2024 (GLOBE NEWSWIRE) -- Today, Emergent BioSolution...